Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of recombinant factor VIII-Fc fusion protein in adolescents and adults with hemophilia A
ChiCTR2000034091Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human coagulation factor viii-fc fusion protein in hemophilia A (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Bleeding symptoms and signs improvement score, Annualized bleeding rate and 1 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
recombinant human coagulation factor viii-fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2000034091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034091.